- Home
- ROIV vs ES Comparison
ROIV vs ES Comparison
Compare ROIV & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | ES |
|---|---|---|
| Founded | 2014 | 1927 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 26.9B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ES |
|---|---|---|
| Price | $35.43 | $65.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 16 |
| Target Price | $48.08 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 6.0M | 2.3M |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 4.79% |
| EPS Growth | N/A | ★ 100.88 |
| EPS | N/A | ★ 1.75 |
| Revenue | $8,260,000.00 | ★ $13,547,244,000.00 |
| Revenue This Year | $530.75 | $1.60 |
| Revenue Next Year | $685.92 | $4.92 |
| P/E Ratio | ★ N/A | $37.54 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $15.99 | $62.72 |
| 52 Week High | $42.50 | $76.57 |
Technical Indicators
Market Signals| Indicator | ROIV | ES |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 44.25 |
| Support Level | $33.15 | $62.72 |
| Resistance Level | $35.70 | $71.44 |
| Average True Range (ATR) | 1.14 | 0.98 |
| MACD | -0.34 | 0.33 |
| Stochastic Oscillator | 35.90 | 72.27 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.